Long-Term Managed Access Program (MAP) Data Confirm Sustained eGFR Stabilization with Iptacopan up to 24 Months in C3 Glomerulopathy (C3G) (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0674; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Conclusion This long-term MAP data corroborates the benefit of iptacopan treatment demonstrated in the clinical trials, showing sustained eGFR stabilization in pts with native and recurrent C3G up to 24 mo in the real world. Iptacopan was well tolerated with no new safety signals identified."
Complement-mediated Rare Disorders • Glomerulonephritis • Nephrology • Renal Disease • CFB
|
|
Carla M. Nester; Luigi Biancone; Josep Miquel Blasco Pelicano; Teresa Cavero; Gianluigi Ardissino; Sohini Raha; Sviatlana Rizk; Shantanu Kamboj; Abdul Faheem Khan; Anna Aldea; Serge Smeets
|